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Nicotinamide adenine dinucleotide (NAD+) is an important molecule with extensive
biological functions in various cellular processes, including protection against cell
injuries. However, little is known regarding the roles of NAD+ in neuronal excitation
and excitotoxicity associated with many neurodegenerative disorders and diseases.
Using patch-clamp recordings, we studied its potential effects on principal neurons
in the ventral cochlear nucleus (VCN), which is particularly vulnerable to bilirubin
excitotoxicity. We found that NAD+ effectively decreased the size of evoked excitatory
postsynaptic currents (eEPSCs), increased paired-pulse ratio (PPR) and reversed the
effect of bilirubin on eEPSCs, implicating its inhibitory effects on the presynaptic release
probability (Pr). Moreover, NAD+ not only decreased the basal frequency of miniature
EPSCs (mEPSCs), but also reversed bilirubin-induced increases in the frequency of
mEPSCs without affecting their amplitude under either condition. Furthermore, we found
that NAD+ decreased the frequency of spontaneous firing of VCN neurons as well
as bilirubin-induced increases in firing frequency. Whole-cell current-clamp recordings
showed that NAD+ could directly decrease the intrinsic excitability of VCN neurons
in the presence of synaptic blockers, suggesting NAD+ exerts its actions in both
presynaptic and postsynaptic loci. Consistent with these observations, we found that
the latency of the first postsynaptic spike triggered by high-frequency train stimulation
of presynaptic afferents (i.e., the auditory nerve) was prolonged by NAD+. These
results collectively indicate that NAD+ suppresses presynaptic transmitter release and
postsynaptic excitability, jointly weakening excitatory neurotransmission. Our findings
provide a basis for the exploration of NAD+ for the prevention and treatment of bilirubin
encephalopathy and excitotoxicity associated with other neurological disorders.
Keywords: nicotinamide adenine dinucleotide (NAD+), ventral cochlear nucleus, patch-clamp recording,
miniature excitatory postsynaptic currents (mEPSCs), evoked EPSCs (eEPSCs), spontaneous spike, bilirubin
encephalopathy, hyperexcitation
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INTRODUCTION
Emerging evidence indicates that nicotinamide adenine
dinucleotide (NAD+) plays essential roles in energy metabolism,
mitochondrial functions, aging, calcium homeostasis, immune
functions and gene expression (Ying, 2006, 2008; Xia et al.,
2009). A series of studies have shown that NAD+ treatment
can significantly decrease cell death induced by oxidative stress
(Alano et al., 2004), oxygen-glucose deprivation (Wang et al.,
2008), genotoxic agents and zinc (Cai et al., 2006). Despite the
wide range of biological functions of NAD+ in cellular processes,
little attention has been paid to the action of NAD+ on neuronal
excitation and its protective effect on excitotoxicity, which is
closely related to neuronal injury in many neurodegenerative
diseases. A previous study showed that poly(ADP-ribose)
polymerase-1 (PARP-1), a major NAD+-consuming enzyme,
is involved in glutamate NMDA receptor-dependent neuronal
death (Cosi et al., 2004). Moreover, NAD+ was implicated
in inhibiting apoptotic neuronal death after glutamate insult
(Wang et al., 2014), implicating the potential of NAD+ in
protecting neurons from excitotoxicity under pathological
conditions.
Excitotoxicity was proposed as one of the major mechanisms
underlying bilirubin (Bil) encephalopathy (Watchko, 2006;
Watchko and Tiribelli, 2013), a devastating neurological disorder
that results from preferential bilirubin toxicity in neurons,
with a regional topography of injuries to specific nuclei in
the central nervous system (CNS; Ostrow et al., 2003). Our
previous studies showed that bilirubin could induce neuronal
hyperexcitation via the potentiation of presynaptic glutamate
release in the ventral cochlear nucleus (VCN) and lateral superior
olive nucleus (LSO), which are most vulnerable to bilirubin (Li
et al., 2011, 2012). It is known that glutamate excitotoxicity
is linked to bilirubin encephalopathy, which can be attributed
to the deposition of unconjugated bilirubin in selective brain
areas during neonatal hyperbilirubinemia. However, there are no
effective pharmacological treatments to alleviate the toxic effects
associated with hyperbilirubinemia.
To explore the potential utility of NAD+ for neuroprotection,
we made patch-clamp recordings from VCN neurons in acute
auditory brainstem slices from early postnatal rats (<2 weeks
old), and investigated the effects of NAD+ on synaptic
transmission and neuronal excitability with or without addition
of bilirubin to simulate neonatal hyperbilirubinemia. Our results
demonstrated that NAD+ inhibits presynaptic glutamate release
and downregulates the intrinsic excitability of postsynaptic
neurons, ultimately attenuating neuronal excitation. More
importantly, NAD+ reversed and prevented bilirubin-induced
hyperexcitation in VCN neurons.
MATERIALS AND METHODS
Ethics Statement
Experiments were conducted in conformity with the guiding
principles for the care and use of animals, and experimental
protocols were approved by the Ethics Review Committee for
Animal Experimentation of Shanghai Jiao Tong University.
All protocols were developed in accordance with the National
Institutes of Health guide for the care and use of laboratory
animals. Throughout the experiment, all efforts were made to
alleviate animal suffering.
Slice Preparation and Solutions
Experiments were conducted using brain slices of the VCN
obtained from 5- to 12-day-old Sprague-Dawley rats, which were
killed by decapitation under sodium pentobarbital (55 mg/kg,
i.p.) anesthesia. Each brain was submerged in ice-cold artificial
CSF (ACSF) containing (in mM): 124 NaCl, 5 KCl, 1.2 KH2PO4,
2.4 CaCl2, 1.3 MgSO4, 24 NaHCO3 and 10 glucose, saturated
with 95% O2 and 5% CO2. The brain region containing the
VCN was sectioned into transverse slices (300 µm thick)
using a vibratome (VT-1000s, Leica, Germany). Brain slices
were pre-incubated in ACSF with 95% O2 and 5% CO2 for
40–60 min at 35–37◦C. The VCN was visually identified
in slices with a 40× water immersion objective attached
to an upright microscope (ECLIPSE FN1, Nikon, Japan).
The neurons with normal morphological appearance and
stable electrophysiological activity, i.e., miniature excitatory
postsynaptic currents (mEPSCs), evoked EPSCs (eEPSCs) and
firings, in the VCN were chosen for experiments.
Drug Application
The drugs used in this study included bilirubin, β-NAD+,
bicuculline, strychnine, 6-Cyano-7-nitroquinoxaline-2,3-dione
(CNQX) and D-(-)-2-Amino-5-phosphonopentanoic acid
(APV). Chemicals and drugs were all purchased from Sigma
unless indicated otherwise. Bilirubin was dissolved in 0.1 M
NaOH at 1 mM as a stock solution, stored in disposable
aliquots in the dark at −20◦C (for <48 h), and diluted to a final
concentration of 3 µM before use. Bilirubin was kept away from
light both in stock solution and during all experiments. NAD+
was dissolved in distilled water and kept as a stock solution
in 10-µL aliquots at −20◦C. The NAD solution was used for
no more than 5 days after preparation. Tetrodotoxin (TTX)
was purchased from Alomone Laboratories (Jerusalem, Israel)
and was prepared as concentrated stock solutions in distilled
water and stored in 20-µL aliquots at −20◦C. The application
of drugs was achieved using a multi-valve gravity perfusion
system.
Electrophysiology
Whole-Cell Voltage-Clamp Recording of Evoked and
Miniature EPSCs
VCN neurons were visually identified using a CCD camera
with light filtered to pass visible and infrared. mEPSCs were
recorded at a holding potential of −60 mV in the voltage-clamp
mode. Pipettes (World Precision Instruments) had a resistance
of 3–5 MΩ when filled with an internal solution containing
the following (in mM): 127 CH3CsO3S, 20 NaCl, 20 HEPES,
0.4 EGTA, 5 tetraethylammonium chloride (TEA-Cl), 3 QX314-
Cl, 2.5 NaATP and 0.3 GTP. The pH was 7.2 and adjusted with
Tris-base. The bath offset potential and electrode capacitance
were compensated before sealing onto the cell membrane. The
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series resistance was compensated by 75%–90%. Series resistance
varied from 5 to 15 MΩ among cells in this study and was
checked and adjusted every series to keep it below 15 MΩ all
along the recordings in one cell. Cells showing the changes
in series resistance more than 15% during recordings were
omitted from the analysis. Bicuculline (10 µM) strychnine
(1 µM) and 1 µM TTX were added to the ACSF to suppress
inhibitory currents mediated by GABA, glycine and synaptic
currents evoked by action potentials, respectively. To measure
evoked EPSCs, a bipolar stimulation electrode was positioned
to the auditory nerve stub to stimulate afferent inputs to the
recorded cell. Recordings were made 200–400 µm away from
the stimulation electrode. The threshold to evoke EPSCs was first
measured by varying the stimulation intensity from 0 to 20 V.
The stimulus strength was adjusted to be 1.5–2× of threshold in
order to elicit reliable minimal EPSCs. Paired-pulses stimulations
with inters-pulse time interval of 20 ms were repeated for
15 times with inter-trial interval of 15 s in control, during drug
application and wash solutions respectively.
Whole-Cell Current-Clamp Recordings of Spike
Firings Driven by Presynaptic Release or Current
Injections
Pipettes were filled with an internal solution containing the
following (in mM): 97.5 K-gluconate, 32.5 KCl, 0.5 EGTA,
40 HEPES, 1 MgCl2, 0.3 GTP and 2 MgATP. The pH was
7.2 and was adjusted with Tris-base. Upon breakthrough of
membrane patch, the resting potential of VCN neurons was
about −45 to −60 mV. To examine postsynaptic spike firings
driven by presynaptic inputs, VCNneurons were held at−70mV
by a hyperpolarization current (−50 to −250 pA) while the
auditory nerves were stimulated with a bipolar electrode in a
100 Hz train of five pulses for 15 trials with inter-trial interval
of 15 s. The shock intensity was also set at 1.5–2× above the
threshold. To examine the intrinsic excitability of VCN neurons,
action potentials were elicited from the membrane potential of
−70 mV using a series of current injection steps (from −300 to
+300 pA with 50-pA increments) in the presence of synaptic
blockers of CNQX (40 µM), APV (50 µM), bicuculline (10 µM)
and strychnine (1 µM) in ACSF solution.
Cell-Attached Recording
Spontaneous action potential currents were recorded from
neurons under voltage-clamp mode with a pipette potential of
−60 mV. Pipettes with a resistance of 4–6 MΩ were filled
with an internal solution containing the following (in mM):
97.5 K-gluconate, 32.5 KCl, 0.5 EGTA, 40 HEPES, 1 MgCl2,
0.3 GTP and 2 MgATP. The pH was 7.2 and was adjusted
with Tris-base. All recordings were conducted under a gravity
perfusion system at a speed of 1 ml/min of ACSF continuously
gassed with 95% O2 and 5% CO2. All data were acquired
by EPC10 (HEKA, 2.9 kHz Bessel filter; LIH 1600 sampled
at 10 kHz) with Patch master software or MultiClamp-700B
(Axon, 5 kHz low-pass-filtered; 1550, sampled at 50 kHz) with
pClamp6 software. All experiments were performed at room
temperature (23–27◦C).
Data Analysis
All data were stored on a personal computer for further analysis.
The numbers of mEPSCs and spontaneous spikes were counted
and analyzed with the MiniAnalysis Program (Synaptosoft, NJ,
USA), with thresholds 2.5 times the root mean square of the
baseline noise, which was typically 6 pA for mEPSCs and
10 pA for spontaneous spike currents. Peaks were detected
automatically, but each detected event was then inspected by
eye to prevent the inclusion of artifacts. As synaptic charge is
less affected by dendritic filtering and series resistance filtering
effects, we compared the effect on the first evoked EPSC and on
paired-pulse ratio (PPR) by measuring the charge (time integral)
of evoked EPSCs to provide a relatively filtering-independent
assessment of synaptic conductance. The first spike latency was
measured from the onset of a shock to the first peak of the
postsynaptic action potential. Action potential threshold was
defined as mV at the inflection point on the rising phase.
Action potential amplitude was defined as the difference in
mV between the peak and threshold. Duration was defined as
ms at half maximal amplitude. Rise time was defined as ms
of depolarization time from the threshold to the peak. The
charge integral of evoked EPSCs and the amplitude of spike
latency were analyzed with Clampfit 10.2 (Axon Instruments).
The control period was always 6 min in all experiments and
the time window used for frequency evaluation was 3 min
after the firing activity of the cell reached stability (usually
after 3-min recordings). The duration for all drug applications
is 8 min and the time window used for frequency evaluation
is 6 min after we ensure the drug is working (usually after
2-min recordings). The time for wash was 5 min and the
time window used for frequency evaluation is the last 3 min,
namely 2 min after switching back perfusion device to the
control solution. The average values of mEPSC frequencies and
spike frequencies under control conditions were normalized to
1.0 in Figures 1, 3, 5, and were reported as absolute values in
the text. The frequency of all synaptic events were provided
both as the means ± SEMs and scaled to control values.
Statistical analyses were performed using SPSS 17.0 software
(SPSS Inc., Chicago, IL, USA). Values in the text and figures are
provided as the means ± SEMs. Differences in the frequency
and amplitude of the mEPSCs, the charge of evoked EPSCs
and the spike latency were evaluated by one-way analysis of
variance (ANOVA) with Student-Newman-Keuls post hoc test,
and the rates of spontaneous spikes were evaluated by Kruskal-
Wallis non-parametric test, with P < 0.05 used as the level of
significance.
RESULTS
NAD+ Decreased the Release of Glutamate
from Presynaptic Terminals
The VCN can be readily found on the ventral aspect of the
inferior peduncle under the microscope. We focused the present
study on stellate cells which represent one of the major cell
types in the VCN, and can be visually identified from their large
soma size andmultipolar shape and long dendrites. To determine
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whether NAD+ affects basal presynaptic glutamate release, we
examined evoked EPSCs and mEPSCs from stellate cells before
and after the application of 0.5 mM NAD+. In response to two
consecutive stimuli to the auditory nerves, these cells showed
typical paired-pulse facilitation. Application of NAD+ caused
a substantial decrease in the charge of the first eEPSCs to
76% ± 6.8% of control (n = 10, P < 0.05; Figures 1A,C). When
we calculated (PPR = P2/P1), we found NAD+ significantly
increase the PPR from 1.2 ± 0.08 to 1.5 ± 0.09 in the presence
of NAD+ (n = 10, P < 0.01; Figure 1D), implying NAD+
can reduce the release probability at the nerve terminal. In
line with this interpretation, we found that bath application
of NAD+ (0.5 mM) could also significantly decrease mEPSC
frequency from 4.6 ± 0.7 Hz to 2.7 ± 0.5 Hz (57% ± 6.1% of
the control; n = 9, P < 0.01) without influencing its amplitude
(90% ± 4.2% of the control; n = 9, P > 0.05). The mEPSC
frequency recovered to 3.1 ± 0.4 Hz (73.1 ± 10% of the
control) after NAD+ washout (n = 9, P > 0.05; Figures 1E,F,H).
In contrast, five control experiments showed that mEPSCs
were stable over the same recording period of time (from
7.7 ± 2.2 Hz to 8 ± 2.6 Hz, 101% ± 8.6% of control; n = 5,
P > 0.05), suggesting that NAD+-induced decrease was not
due to run-down of mEPSCs (Figure 1G). These results further
indicate that NAD+ suppresses basal presynaptic glutamate
release under physiological conditions.
NAD+ Inhibited the Bilirubin-Induced
Potentiation of Presynaptic Glutamate
Release
Previous studies demonstrated that bilirubin can increase
presynaptic glutamate release (Li et al., 2011). To explore
whether NAD+ can influence bilirubin-induced potentiation, we
recorded the eEPSCs and mEPSCs with sequential application
of bilirubin and NAD+. Consistent with the previous results
from our laboratory, application of bilirubin caused a substantial
increase in the charge of the first eEPSCs to 121.4% ± 9.6%
of control (n = 7, P < 0.05). Subsequent co-application
with NAD+ (0.5 mM) could completely reverse the excessive
glutamate release induced by bilirubin to 93.6 ± 6.6% of
control (n = 7, P > 0.05; Figures 2A,B). When we calculated
PPR, we found bilirubin significantly decrease the PPR from
0.97 ± 0.05 to 0.74 ± 0.03 (n = 10, P < 0.05). This effect
could be partially reversed by NAD+ from 0.74 ± 0.05 to
0.97 ± 0.03 (n = 7, P < 0.05; Figures 2A,C). We also
found that application of bilirubin markedly increased the
frequency of mEPSCs from 11.3 ± 7.2 Hz to 17.7 ± 9.9 Hz
(235 ± 41% of the control; n = 6, P < 0.01). Subsequently,
co-application with 0.5 mM NAD+ significantly decreased the
frequency of mEPSCs from 17.7 ± 9.9 Hz to 6.1 ± 3.4 Hz
(88 ± 27% of the control; n = 6, P > 0.05; Figures 3A,D).
In contrast, control experiments showed that the increased
FIGURE 1 | Effects of nicotinamide adenine dinucleotide (NAD+) on miniature excitatory postsynaptic currents (mEPSCs) and evoked EPSCs.
(A) Evoked EPSCs recorded from a neuron in the presence of strychnine and bicuculline. NAD+ decreased the response charge in this cell. (B) EPSCs was evoked
in a neuron during paired-pulse stimuli with an interval of 20 ms. NAD+ decreased the first EPSC (P1) but increased the paired-pulse ratio (PPR; P2:P1) in this cell.
Stimulation artifacts were manually removed to improve the clarity in (A,B). (C) Mean value of normalized charge of the first EPSC in control, during NAD+ and
washout solutions. (D) Mean value of PPR of EPSC charge in control, during NAD+ and wash solutions. (E) Typical mEPSCs recorded from a neuron during control,
0.5 mM NAD+, and washout. (F) Time course of average amplitude of mEPSCs along sample experiments of Panel (E). (G) Representative time course of the effect
of NAD+ on normalized frequency of mEPSCs in a neuron. The control solution was applied for 6 min, followed by the bath application of 0.5 mM NAD+ for 8 min.
The frequencies of mEPSCs were measured for last 3 min in control and last 6 min in NAD+ (blue circles). By comparison, in a control experiment the same
measurement was made with only vehicle application (black circles). (H) Histograms depicting the effect of NAD+ on mEPSCs frequency and amplitude. Error bars
represent standard error; ∗P < 0.05; ∗∗P < 0.01; ns: not significant, one-way analysis of variance (ANOVA) with Student-Newman-Keuls post hoc test.
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FIGURE 2 | NAD+ reverses bilirubin induced enhancement in evoked excitatory synaptic transmission. (A) Evoked EPSCs recorded from a neuron in the
presence of strychnine and bicuculline. EPSCs was evoked in a neuron during paired-pulse stimuli with an interval of 20 ms. Bilirubin enhanced the first EPSC (P1)
but decreased the PPR (P2:P1) in this cell and the effect was reversed by NAD+. Stimulation artifacts were manually removed to improve the clarity in (A). (B) Mean
value of normalized charge of the first EPSC in control, bilirubin, bilirubin plus NAD+ and wash respectively and washout solutions. (C) Mean value of PPR of EPSC
charge in control, bilirubin, bilirubin plus NAD+ and wash solutions respectively. Error bars represent standard error; ∗P < 0.05; ns: not significant, one-way ANOVA
with Student-Newman-Keuls post hoc test.
frequency in mEPSCs was sustained in the continuous presence
of bilirubin, suggesting that NAD+-induced decrease was
not due to mEPSC run down and that NAD+ indeed
suppressed bilirubin-induced potentiation of glutamate release
(Figure 3C). There was no significant change in the mEPSC
amplitude throughout the experiment (Figure 3B). These
results indicate that NAD+ can inhibit the bilirubin-induced
potentiation of presynaptic glutamate release onto stellate cells
in VCN.
NAD+ Decreased the Frequency of
Spontaneous Spiking in VCN Neurons
To investigate whether NAD+ could influence the neuron
excitability, we examined the effect of NAD+ on the frequency
of spontaneous spikes in the cell-attached configuration using
the voltage-clamp mode. After recording a stable 3-min baseline,
NAD+ in different concentrations was applied to the recording
brain slice. Only recordings with control firing frequency lower
than 6 Hz (80% of cases) were included in the analysis.
Figures 4A,B illustrated typical neurons after perfusion of
0.5 mM and 2 mM NAD+. NAD+ application decreased firing
frequency significantly (P < 0.05). The spontaneous spike
frequencies were decreased in a dose-dependent manner from
4.5 ± 1.6 Hz to 4.3 ± 1.5 (91.3 ± 7.3% of the control; n = 9,
P > 0.05) at 0.1 mM, from 5.7 ± 1.0 Hz to 4.7 ± 1.0 Hz
(84.6 ± 2.3% of the control; n = 9, P < 0.01) at 0.5 mM, from
5.3 ± 1.7 Hz to 2.7 ± 1 Hz (40.5 ± 3.2% of the control; n = 9,
P < 0.01) at 1 mM and from 5.2 ± 1.4 Hz to 1.5 ± 0.5 Hz
(28.9 ± 3.7% of the control; n = 9, P < 0.01) at 2 mM,
respectively, during 6-min application period (Figure 4C). Thus,
these results indicated that neuronal excitability was highly
sensitive to NAD+ with a concentration as low as 0.5 mM,
being able to induce a significant decrease in the frequency of
spontaneous spikes.
NAD+ Inhibited and Prevented
Bilirubin-Induced Hyperexcitation
To clarify whether the hyperexcitation induced by bilirubin
can be reversed by NAD+, we examined the effect of NAD+
on spontaneous spiking following bilirubin application. The
application of bilirubin significantly increased the rate of
spontaneous firing from 1.8 ± 1.0 Hz to 4.1 ± 1.9 Hz
(191 ± 2.3%, n = 5, P < 0.01). Subsequent co-application
with NAD+ (0.5 mM) could completely reverse the excessive
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FIGURE 3 | NAD+ inhibited the bilirubin-induced potentiation of mEPSCs. (A) Typical mEPSCs were recorded from each neuron for 3, 6, 6 and 3 min time
blocks in control, bilirubin, bilirubin plus NAD+ and wash respectively. (B) Time course of average amplitude of mEPSCs along sample experiments of Panel (A).
(C) Representative time course of the effect of bilirubin-induced potentiation of normalized mEPSC frequency in a neuron. Typical time course of mEPSC frequency
in a neuron with control period (in black) for 3 min followed by bilirubin application alone (in red) for 21 min is shown. (D) Mean values of normalized mEPSC
frequencies and amplitudes before, during and after drug administration. Error bars represent the standard error; ∗P < 0.05; ∗∗P < 0.01; ns: not significant, one-way
ANOVA with Student-Newman-Keuls post hoc test.
FIGURE 4 | NAD+ inhibited frequency of spontaneous spikes in ventral cochlear nucleus (VCN) neurons in a dose-dependent manner. (A) Typical
spontaneous spikes were recorded from a neuron in control, NAD+ (0.5 mM), and wash respectively. (B) Typical spontaneous spikes were recorded from a neuron in
control, NAD+ (2 mM) and wash respectively. (C) Group results shows the effect of NAD+ in different concentrations(0.1 mM, 0.5 mM, 1 mM and 2 mM) on the
normalized frequency of spontaneous activity. Error bars indicate standard deviation; ∗P < 0.05; ∗∗P < 0.01; ns: not significant, one-way ANOVA with
Student-Newman-Keuls post hoc test.
spontaneous firings induced by bilirubin from 4.1 ± 1.9 Hz
to 1.8 ± 1.1 Hz (85 ± 2.2% of the control value; n = 5,
P < 0.05). After NAD+ and bilirubin were removed, the
frequency rebounded to 1.7 ± 1.1 Hz (73 ± 5.6% of the
control; n = 5, P > 0.05; Figures 5A,D). In contrast,
control experiments showed that the frequency of spikes did
not decrease in continuous bilirubin application, suggesting
that NAD+-induced decrease was not due to cell run down
and NAD+ can attenuate bilirubin-induced hyperexcitation
(Figure 5C).
Next, to investigate whether NAD+ can prevent bilirubin-
induced hyperexcitation, we pretreated recording neurons with
0.5 mM NAD+ before bilirubin application. NAD+ at 0.5 mM
significantly decreased the spontaneous spike frequency from
8.2 ± 0.8 Hz to 7.2 ± 0.5 Hz (90 ± 2.8% of the control, n = 5,
P< 0.05). In the presence of NAD+, further addition of bilirubin
had no significant influence on frequency of spontaneous spikes
(from 7.2± 0.5 Hz to 7.2± 0.7 Hz, n = 5, P> 0.05; Figures 5B,E).
These results suggest that NAD+ effectively precluded bilirubin-
induced hyperexcitation in VCN neurons.
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FIGURE 5 | NAD+ prevented and suppressed bilirubin-induced hyperexcitation. (A) Typical spontaneous spikes were recorded from a neuron in control
solution, bilirubin, bilirubin plus NAD+ and wash respectively. (B) Typical spontaneous spikes were recorded from a neuron in control solution, NAD+, bilirubin plus
NAD+ and wash respectively. (C) Typical time course of normalized spike frequency in a neuron with control solution for 3 min followed by bilirubin application alone
for 21 min. (D) Mean values of normalized spontaneous spike frequencies of five neurons in control, bilirubin, bilirubin plus NAD+ and wash. (E) Mean values of
normalized spontaneous spike frequencies of five neurons in control, NAD+, bilirubin plus NAD+ and washout. Error bars represent the standard error; ∗P < 0.05;
∗∗P < 0.01; ns: not significant, Kruskal-Wallis non-parametric tests.
NAD+ Decreased the Neuronal Intrinsic
Excitability
Our observations showingNAD+ can dampen basal spontaneous
spike firings in VCN neurons raised the possibility that the
intrinsic excitability of VCN neurons might be dampened,
independent its inhibitory effects on presynaptic glutamate
release. To test this, we performed current-clamp recordings
and examined the input-output relationship of stellate cells by
injecting a series of current steps (−300 to +300 pA, 50-pA
increments; Figure 6A). Spike numbers at each current step were
counted as a measure of the membrane excitability and plotted
against the magnitude of current step injections. We found that
application of a cocktail of blockers for inhibitory and excitatory
receptors (10 µM bicuculline, 1 µM strychnine, 40 µM CNQX
and 50 µM APV) had little effects on the input-output curves,
suggesting spontaneous transmitter release contributed little to
the basal neuronal excitability. In contrast, subsequent addition
of NAD+ significantly decreased the number of evoked spikes
(n = 9), without affecting the input resistance as seen from the
steady-state I-V plots measured near the end of current injections
(Figures 6B,C), indicating that NAD+ attenuates the intrinsic
excitability of VCN neurons. However, the first action potential
properties of VCN neurons did not change during the whole
period (Table 1).
The inhibitory effects of NAD+ on the intrinsic excitability
of postsynaptic neurons as well as presynaptic release (Figure 1)
led us to hypothesize that such dual effects of NAD+ could
decrease the fidelity of neurotransmission. To test this, we
performed current-clamp recordings of postsynaptic firings
driven by presynaptic stimulation with short trains of shocks
to the auditory nerve fibers at 100 Hz. As illustrated in
Figure 6D, we found that both the latency of the first
spike (relative to the stimulation artifact) and total number
of spikes were dramatically impacted by NAD+. In line
with the effects of NAD+ on EPSCs under voltage-clamp
mode (Figure 1), the amplitude of the excitatory postsynaptic
potentials (EPSPs) were significantly attenuated to delay the
onset of the first spike, as reflected by increases in the latency
from 6.5 ± 3 ms to 16.8 ± 7.4 ms after NAD+ application
(n = 6, P < 0.05). This delay was partially recovered to
9.2± 5ms after NAD+was removed (Figure 6E). All six neurons
showed longer AP latency despite that the responses were
quite variable among cells. These results suggested that NAD+
potently dampened neuronal excitation by simultaneously
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FIGURE 6 | Effects of NAD+ on neuronal intrinsic excitability and excitatory neurotransmission. (A) Example traces of APs evoked by depolarizing currents
(top panel) from a VCN neuron. Synaptic blockers including 10 µM bicuculline, 1 µM strychnine, 40 µM CNQX and 50 µM APV to block GABA, Glycine, AMPA and
NMDA transmitter. (B) Voltage-current relations in three conditions. Steady-state potential is measured at the lowest point of the membrane potential in response to
hyperpolarizing current steps. (C) The number of spikes generated by various depolarization steps from the cells in Panel (D). (D) Averaged example traces of
neurons in VCN response to auditory nerve shocks. A train of five suprathreshold shocks was delivered to the auditory nerve root at 100 Hz. Trains were repeated
15 times with inter-trial interval of 15 s in control, during NAD+ and wash solutions separately. Stimulation artifacts were manually truncate to for clarity. (E) The first
spike latency in control (black bar), NAD+ (blue bar) and washout (orange bar) solutions. Error bars represent standard error; ∗P < 0.05; ns: not significant, one-way
ANOVA with Student-Newman-Keuls post hoc test.
attenuating presynaptic glutamate release and postsynaptic
intrinsic excitability in VCN.
DISCUSSION
NAD+ is a ubiquitous molecule with multifaceted biological
functions in various biological processes (Ying, 2008). The
maintenance of theNAD+ level in the blood or brain is critical for
preserving neuronal bioenergetics and promoting cell survival
(Wang et al., 2008; Ying, 2008). Different mechanisms by which
NAD+ prevents neuronal death have been suggested, but there
is a lack of evidence for its effect on neuronal excitation and
excitotoxicity associated with many neurodegenerative diseases.
In the present study, we explored the effect of NAD+ on
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TABLE 1 | Electrophysiological properties of the first action potential of ventral cochlear nucleus (VCN) neurons.
Control n Synaptic blockers n Synaptic blockers + NAD+ n
AP threshold (mV) −34.9 ± 1.2 9 −36.7 ± 1.5 9 −38.2 ± 1.6 9 ns
AP amplitude (mV) 67.6 ± 5.6 9 67.4 ± 5.1 9 66.5 ± 5.3 9 ns
AP duration (ms) 1.1 ± 0.1 9 1.3 ± 0.2 9 1.4 ± 0.2 9 ns
AP rise time (ms) 1.1 ± 0.2 9 1.3 ± 0.3 9 1.1 ± 0.2 9 ns
Data are means ± SEM. ns, not significant.
neuronal excitation and overexcitation induced by bilirubin
in VCN neurons. Our results showed that NAD+ decreased
presynaptic glutamate release as evidenced by attenuated charge
of eEPSCs and increases in PPR and mEPSC frequency. In
parallel, postsynaptic neuronal excitability was also reduced as
reflected by the decreased number of neuronal firings in response
to the same depolarizing current injections. These data indicated
that NAD+ exerts its effects in both pre- and postsynaptic loci in
VCN neurons.
The mechanisms underlying the effects of NAD+ on
excitatory neurotransmission and membrane excitability
remain unknown. It was reported that NAD+ potentiates
sodium-activated potassium channels (KNa; Tamsett et al.,
2009), which may potentially hyperpolarize the resting
membrane potential and attenuate repetitive firings,
dampening neuronal excitation. Our results indicate that
NAD+ attenuates the intrinsic excitability of VCN neuron
by decreasing the number of evoked spikes, raising the
possibility that activation of certain channels such as
KNa by NAD+ may attenuate repetitive firing instead of
individual spike. However, KNa channels are not expressed
in these cells (Rothman and Manis, 2003), and neither the
resting membrane potential nor the 1st spike waveform was
significantly changed by NAD+ (control: −56.7 ± 3.1 mV;
NAD+: −57.9 ± 3.3 mV, n = 6, P > 0.05), making KNa
an unlikely candidate for NAD+ to exert action. Stellate
cells in VCN have low-voltage-activated potassium (IKL)
and hyperpolarization-activated (Ih) conductances (Oertel
et al., 2008), which may be potential targets for NAD+ to
attenuate the neuronal excitability. Further studies are required
to identify specific conductances which NAD+ specifically
act on.
NAD+ can inhibit both basal synaptic transmission as well
as bilirubin-induced increase in glutamate release, suggesting
that NAD+ can attenuate glutamate release via unknown
mechanisms. Given the fact that bilirubin can induce an increase
in intracellular Ca2+ (Watchko and Tiribelli, 2013), we speculate
that NAD+ acts on either presynaptic Ca2+ channels or intra-
terminal Ca2+ handling to impact the size of eEPSCs and
frequency of mEPSCs, but again additional experiments are
needed to delineate the effects of NAD+ on release. Nevertheless,
our results implicate NAD+ as a potential drug to mitigate
the excitotoxicity induced by bilirubin. The present study
thus not only unravels the novel effects of NAD+ on the
regulation of neuronal excitation under physiological conditions,
but also provides the proof-of-principle for the exploration of
NAD+ for the prevention and treatment of bilirubin-induced
excitotoxicity.
Excitotoxicity is believed to be mediated by the excessive
synaptic release of glutamate and the overstimulation of
glutamate receptors. The excitotoxicity caused by excessive
glutamate is a critical element in the neuropathology of brain
disorders (Sattler and Tymianski, 2001). Glutamate excitotoxicity
has been linked to many acute and chronic neurodegenerative
disorders, such as ischemeia, Parkinson’s disease and bilirubin
encephalopathy (Lau and Tymianski, 2010; Li et al., 2011).
Glutamate receptor-based therapeutics for excitotoxicity have
slowly emerged. Compounds such as MK-801, which blocks
glutamate receptors through binding inside the NMDA receptor-
associated ion channel and thus prevents Ca2+ flux, showed
severe CNS-mediated side effects in patients (Foster and Kemp,
2006). A solution to this problem may lie in the development
of agents that target other processes of excitotoxicity with
fewer side effects. A recent study showed that NAD+ could
effectively reduce apoptotic neuronal death after neurons were
challenged with excitotoxic glutamate stimulation (Wang et al.,
2014). The administration of NAD+ has been shown to
have protective effects on ischemeic brain injury, Parkinson’s
disease and traumatic brain injury (Ying et al., 2007; Won
et al., 2012). Furthermore, the results of the present study
demonstrate that NAD+ can reverse the bilirubin-induced
glutamate release and neuronal hyperexcitation, and block the
bilirubin-induced neuronal hyperexcitation, reinforcing the idea
that NAD+ may have preventive and therapeutic potential for
managing bilirubin encephalopathy. Suppressing the intrinsic
excitability of postsynaptic neurons by NAD+ may further
attenuate Ca2+ overload during intense activity, expanding its
protective action to relieve excitotoxicity in various neurological
disorders.
In conclusion, our study demonstrated that NAD+ can
markedly decrease basal neuronal excitation as well as
over-excitation induced by bilirubin by attenuating presynaptic
glutamate release and postsynaptic intrinsic excitability,
potentially contributing to its neuroprotective effects. These
results provide new information beyond the previously known
effects of NAD+ on neuronal function, lending support to NAD+
as a promising agent for both the treatment and prevention of
neurotoxicity associated with hyperbilirubinemia and other
neurodegenerative disorders.
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